Global Blood Therapeutics Options Pop on FDA Buzz

GBT stock is near the top of the Nasdaq this afternoon

by Karee Venema

Published on Dec 3, 2018 at 2:27 PM

Options traders are making a beeline toward Global Blood Therapeutics Inc (NASDAQ:GBT), after the Food and Drug Administration (FDA) agreed to the company's proposal for an accelerated approval pathway for its sickle cell disease (SCD) treatment, voxelotor. The San Francisco-based firm said it would give more details for its plan to submit a New Drug Application (NDA) early next year.

With GBT stock shooting up 52.2% today to trade at $48, most of today's options activity has occurred on the call side. Specifically, 15,400 calls have changed hands so far, compared to fewer than 3,300 puts. This is more than eight times what's typically seen at this point in the day. And in the wake of today's news, short-term volatility expectations have imploded. The stock's 30-day implied volatility is down 50.2% from last Friday's close, to 75% -- in the low 32nd percentile of its annual range.

Analysts have been quick to chime in today, too, with H.C. Wainwright boosting its GBT price target to $150 from $125 -- a 213% premium to current trading levels. Plus, Cantor Fitzgerald reiterated its "overweight" rating and $96 price target, saying current clinical data for voxelotor "offers a compelling treatment option in SCD that lacks disease-modifying therapies." Already, 12 of 13 brokerages maintain a "strong buy" rating on Global Blood Therapeutics, while the average 12-month price target sits all the way up at $81.92.

Not all of the sentiment surrounding the drug stock is upbeat, though, with short sellers controlling roughly one-fifth of the available float. An unwinding of this pessimism could be helping the hot stock, considering it would take shorts nearly two weeks to cover all these bearish bets, at GBT's average daily pace of trading.

Looking at the charts, the stock wrapped up its third straight monthly loss late last week, and has shed 29.4% since its Feb. 21 record high of $68.05. The shares bottomed out at a 13-month low of $30.15 on Friday, and despite pacing for their best day ever today, they are running out of steam near familiar resistance in the round $50 region.

gbt stock daily chart dec 3

Signal Says Take Profits on This Pharma Stock
The shares are testing a familiar ceiling on the charts
What to Make of the S&P Death Cross
It's the index's first death cross in nearly three years
2 Tech Stocks That Could Fade Into the New Year
Tech stocks have been under heavy scrutiny in recent months
From Schaeffer's Pro Traders
Weekly Options Secrets Revealed

Direct from our Schaeffer's traders, your FREE guide to winning with weekly options!


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories

The Shortcut to Earnings Season Profits
A free tool can help traders bank big this earnings season.
Trade Buzz Sparks Roller-Coaster Week For Stocks
The Dow and S&P 500 are heading toward weekly losses
Tariff Buzz Gives Ford a Lift
China announced that it would temporarily halt additional tariffs on U.S.-made autos
This May Be the 21st Century "Oil Boom"
U.S. production of lithium is set to increase 1,300% in the next 2 years.